Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.
Scott D SolomonJohn W OstrominskiMuthiah VaduganathanBrian ClaggettPardeep S JhundAkshay S DesaiCarolyn S P LamBertram PittMichele SenniSanjiv J ShahAdriaan A VoorsFaiez ZannadImran Zainal AbidinMarco Antonio Alcocer-GambaJohn J AthertonJohann BauersachsChang-Sheng MaChern-En ChiangOvidiu ChioncelVijay ChopraJosep Comin-ColetGerasimos FilippatosCândida FonsecaGrzegorz GajosSorel GolandEva GoncalvesováSeok-Min KangTzvetana KatovaMikhail N KosiborodGustavs LatkovskisAlex Pui-Wai LeeGerard C M LinssenGuillermo Llamas-EsperónVyacheslav MareevFelipe A MartinezVojtěch MelenovskýBéla MerkelySavina NodariMark C PetrieClara Inés SaldarriagaJose Francisco Kerr SaraivaNaoki SatoMorten SchouKavita SharmaRichard TroughtonJacob A UdellHeikki UkkonenOrly VardenySubodh VermaDirk von LewinskiLeonid G VoronkovMehmet Birhan YilmazShelley ZierothJames Lay-FlurrieIlse van GamerenFlaviana AmarantePrabhakar ViswanathanJohn J V McMurrayPublished in: European journal of heart failure (2024)
FINEARTS-HF has enrolled a broad range of high-risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.